Ekaterina Pavlenko

Dr. Ekaterina Pavlenko

Sechenov University, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2022 in Genes
Verified
Journal Article
Open access
PDF file
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
Ekaterina PavlenkoEkaterina Pavlenko
Ekaterina Pavlenko
VSVsevolod Sedov
Vsevolod Sedov
KEKogan Evgenija
Kogan Evgenija
MPMargarita Polyak
Margarita Polyak
YLYulia Lutokhina
Yulia Lutokhina
The same variants in sarcomeric genes can lead to different cardiomyopathies within the same family. This gave rise to the concept of a continuum of sarcomeric cardiomyopathies. However, the manifestations and evolution of these cardiomyopathies in pathogenic variant carriers, including members of the same family, remains poorly understood. We present a case of familial sarcomeric cardiomyopathy caused by heterozygous truncating pathogenic variant p.Q1233* in cardiac myosin-binding protein C (MyBPC3) gene. The proband was first diagnosed with restrictive cardiomyopathy combined with left ventricular noncompaction (LVNC) and sarcoidosis at the age of 64. The predominantly restrictive phenotype of cardiomyopathy is considered to be a result of interaction between LVNC and sarcoid myocarditis. His 39-year-old son and 35-year-old daughter have identical non-obstructive asymmetric hypertrophic cardiomyopathy. The risk of sudden cardiac death in the son is high due to myocardial fibrosis, ischemia and nonsustained VT. We assume that both phenotypes in the family may have originally been different or there may have been a gradual transformation of the hypertrophic phenotype into LVNC. Myocarditis is regarded as an important epigenomic modifier of sarcomeric cardiomyopathy. In the proband and his son, cardioverter-defibrillators were implanted, and the proband experienced appropriate shocks due to ventricular tachycardia/fibrillation. The proband was also treated with corticosteroids. His death at the age of 69 years occurred due to acute gastric hemorrhage accompanied by progressive heart failure. This report confirms the concept of the phenotypic continuum of sarcomeric cardiomyopathies and describes possible phenotypic patterns and their transformation over time.

7 March 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
Ekaterina PavlenkoEkaterina Pavlenko
Ekaterina Pavlenko
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
NVN. V. Varionchik
N. V. Varionchik
ANA. V. Nedostup
A. V. Nedostup
VSVsevolod Sedov
Vsevolod Sedov
EZElena Zaklyazminskaya
Elena Zaklyazminskaya
Регистр взрослых больных с некомпактным миокардом левого желудочка: классификация клинических форм и проспективная оценка их прогрессирования

26 November 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
IAI. N. Alieva
I. N. Alieva
PSP. V. Senchikhin
P. V. Senchikhin
LNL. D. Nazarova
L. D. Nazarova
SCS. V. Chernyavsky
S. V. Chernyavsky
NSN. D. Sarkisova
N. D. Sarkisova

1 January 2016 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
AНArray В. Недоступ
Array В. Недоступ
Ekaterina PavlenkoEkaterina Pavlenko
Ekaterina Pavlenko
VSVsevolod Sedov
Vsevolod Sedov
KEKogan Evgenija
Kogan Evgenija
VSV. A. Sulimov
V. A. Sulimov
ИНФАРКТ МИОКАРДА КАК ТИПИЧНОЕ ПРОЯВЛЕНИЕ НЕКОМПАКТНОЙ КАРДИОМИОПАТИИ.

8 October 2024 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
PSPolina Savina
Polina Savina
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
DAD. Kh. Ainetdinova
D. Kh. Ainetdinova
ASA. V. Sedov
A. V. Sedov
Ekaterina PavlenkoEkaterina Pavlenko
Ekaterina Pavlenko
ЮЛЮ. А. Лутохина
Ю. А. Лутохина
Aim. To study the mechanisms and clinical variants of subacute and chronic myocarditis after SARS-CoV-2 infection using morphological and virological studies and to develop approaches to its treatment.Material and methods. The study included 89 patients with documented coronavirus disease 2019 (COVID-19). The diagnosis of post-COVID myocarditis was established based on myocardial biopsy and/or cardiac magnetic resonance imaging (MRI) data in combination with anamnesis, increased titers of anticardiac antibodies, and other criteria. The average time of presentation after infection was 8,0 [4; 17,5] months, while the average follow-up period was 7,0 [6,0; 13,5] months. Electrocardiography, Holter monitoring, echocardiography, cardiac MRI (n=60), determination of anticardiac antibody levels, myocardial biopsy (n=38), and autopsy (n=1) were performed.Results. All patients showed an association between the onset or exacerbation of cardiac symptoms and COVID-19. The clinical variants of post-COVID myocarditis were identified: arrhythmic (n=24) with newly developed arrhythmias with normal myocardial contractility; decompensated (n=65) with newly diagnosed heart failure, including a variant developed with primary (genetic) cardiomyopathies and amyloidosis (n=10). The profile of arrhythmias in the arrhythmic variant varied from potentially life-threatening rhythm and conduction disorders (sustained ventricular tachycardia, grade II-III atrioventricular block) to infrequent supraventricular premature beats. In the decompensated variant, lymphocytic myocarditis was most often morphologically detected, while eosinophilic and giant cell myocarditis, associated with a worse prognosis, were rarer. Simultaneous development of nonbacterial thrombotic endocarditis, infective endocarditis with the development of valvular heart defects was noted. In 10 cases, myocarditis was combined with primary cardiomyopathies, AL amyloidosis. Treatment included the administration of antiarrhythmic, cardiotropic, immunosuppressive therapy (glucocorticoids 16-32 mg/day in 68,5% of patients, hydroxychloroquine 200-400 mg/day in 33,7%). In the arrhythmic type, complete arrhythmia suppression was achieved in 25% of cases, while partial in 58,3%. In one case, a pacemaker was implanted. In patients with a decompensated myocarditis, corticosteroids were effective regardless of the viral genome/proteins in the myocardium.Conclusion. COVID-19 can induce subacute and chronic myocarditis with the development of isolated arrhythmias or severe heart failure.

23 April 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
OBOlga VLADIMIROVNA Blagova
Olga VLADIMIROVNA Blagova
KEKogan Evgenija
Kogan Evgenija
Ekaterina PavlenkoEkaterina Pavlenko
Ekaterina Pavlenko
ASA.V. Sedov
A.V. Sedov
YLYu.V. Lerner
Yu.V. Lerner
SCS.V. Chernyavskij
S.V. Chernyavskij
Patients with damage of the mitral, aortic and tricuspid valves and systolic myocardial dysfunction associated with previous SARS-CoV-2 infection are described. The diagnosis of acquired defect was established in 4 patients based on medical history, electrocardiography, echocardiography, magnetic resonance imaging of the heart, endomyocardial or intraoperative myocardial biopsy, and in one case, autopsy. The study of the myocardium included H&E, Van Gieson staining, immunohistochemical (IHC) study with antibodies to CD3, CD20, CD45, CD68, to the nucleocapsid and Spike proteins of SARS-CoV-2. Previous valve diseases (prolapse, bicuspid aortic valve) served as a background for the development of the defect in 2 patients. In all cases, IHC studies revealed coronavirus proteins, lymphocytic endocarditis and myocarditis, moderate fibrosis, and signs of connective tissue disorganization. High titers of anticardiac antibodies indicated an autoimmune mechanism for carditis. No signs of infective endocarditis or thromboembolic complications were identified in any case. In patients with an unclear nature of valvular heart defects, a previous new coronavirus infection should be identified and taken into account as a possible etiological factor. The simultaneous development of lymphocytic myocarditis significantly increases the risk of surgical intervention on the valves and requires an integrated approach to treatment.